Sep. 17, 2002 PHILADELPHIA - Many cancer patients generate immune cells capable of specifically attacking their tumors, but the cells rarely do, in fact, target a patient's cancer. What prevents these potentially helpful cells from taking action? And is there anything that might be done to unleash them?
The attack cells - known as cytolytic T cells - are prevented from acting by a second set of immune cells called regulatory T cells, according to a new study from investigators at The Wistar Institute. The research also shows that the regulatory T cells communicate their message of restraint to the cytolytic T cells at a distance, via a messenger chemical called TGF-beta. A report on the study appears in the September 15 issue of Cancer Research.
Previous work has focused on ways to stimulate the cytolytic T cells to act, but the new study suggests that other approaches to bringing them into the battle against cancer might be more effective. For example, a drug that inactivates the regulatory T cells or that blocks the TGF-beta chemical message they send might free the cytolytic T cells to attack a patient's tumor.
"We've known for some time that cancer patients can generate T cells able to attack their tumors," says immunologist Dorothee Herlyn, D.V.M., D.Sc., a professor at The Wistar Institute and senior author on Cancer Research study. "What we discovered in this study is that those patients also produce negatively regulating cells at the same time that keep the attacking T cells in check. The existence of these regulatory cells may help explain how tumors are able to evade the immune system. They also represent a new starting point for thinking about novel anti-cancer treatments."
The current study evolved somewhat by chance. Using cells from a human colorectal cancer patient, Herlyn's laboratory team was working to identify T cells with cancer-fighting capabilities and isolate them from other types of immune cells. At one point, one of her coworkers suggested combining different groups of isolated cell types to look for interactions between them.
"We put these two different types of immune cell together, one of which killed cancer cells in culture, the other of which did not," Herlyn recalls. "When we did, we were stunned to see that the one that had previously killed cancer cells no longer did so."
Adequately explaining the mechanisms underlying that observation required several years of additional study, she says.
The lead author on the Cancer Research study is Rajasekharan Somasundaram, Ph.D., at The Wistar Institute. The other Wistar-based coauthors are Lutz Jacob, Rolf Swoboda, Ph.D., Laura Caputo, Hong Song, Saroj Basak, David Peritt, Dewei Cai, Brigitte Birebent, Jin Kim, and Klara Berencsi. Collaborators on the study are Dimitri Monos, Ph.D., at the Hospital of the University of Pennsylvania, Francesco Marincola, M.D., at the National Cancer Institute, and Ellen Bloome and Michael Mastrangelo, M.D., a professor of medicine at Thomas Jefferson University. The research was supported by grants from the National Institutes of Health.
The Wistar Institute is an independent nonprofit biomedical research institution dedicated to discovering the causes and cures for major diseases, including cancer, cardiovascular disease, autoimmune disorders, and infectious diseases. Founded in 1892 as the first institution of its kind in the nation, The Wistar Institute today is a National Cancer Institute-designated Cancer Center - one of only eight focused on basic research. Discoveries at Wistar have led to the development of vaccines for such diseases as rabies and rubella, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.
Other social bookmarking and sharing tools:
Note: If no author is given, the source is cited instead.